ERYTECH strengthens its intellectual property position in the US Post author:admERY Post published:April 21, 2015 Post category:Newsroom ERYTECH announces the strengthening of its intellectual property portfolio in the United States with the granting of a new patent and the further extension of the patent term of its core process patent. You Might Also Like ERYTECH Pharma Voting Results by Resolution from Annual General Meeting Held on June 21, 2019 July 4, 2019 ERYTECH announces clinical trial authorizations in Finland and Spain for its European Phase IIb study in AML January 15, 2014 ERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Catalent April 25, 2022
ERYTECH Pharma Voting Results by Resolution from Annual General Meeting Held on June 21, 2019 July 4, 2019
ERYTECH announces clinical trial authorizations in Finland and Spain for its European Phase IIb study in AML January 15, 2014
ERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Catalent April 25, 2022